Promore Pharma
STOCKHOLM, SE / ACCESSWIRE / October 25, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Stockholm 25 October 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announces that a peer-reviewed scientific article describing the results of a clinical study with ropocamptide for the treatment of venous leg ulcers has been published in the journal Wound Repair and Regeneration.
In 2020, Promore Pharma completed a clinical trial, HEAL LL-37, a phase IIb double-blind, randomized, placebo-controlled study aimed at evaluating the efficacy and safety of a new drug, LL-37 / ropocamptide for local administration in combination with compression therapy. The study was performed on 148 patients suffering from difficult-to-heal venous leg ulcers.
Today, the company announces that a scientific article has been published in the journal Wound Repair and Regeneration, which is the journal of the international society in wound care, Wound Healing Society. Co-authors of the article are several internationally renowned subject area experts, including professors Jan Apelqvist, Arkadiusz Jawien, and Folke Sjöberg.
" We are very content that the results of HEAL LL-37 are now published and available to the scientific community and the general public. The publication is a confirmation of the quality of the completed clinical study ", says Jonas Ekblom, CEO of Promore Pharma.
" Once again, we thank all the staff at the healthcare facilities who have participated in the study for their valuable contributions, " says Margit Mahlapuu, CSO of Promore Pharma.
The published article is entitled "Evaluation of LL-37 in Healing of Hard-to-Heal Venous Leg Ulcers: a Multicentric Prospective Randomized Placebo-Controlled Clinical Trial" and can be read in its entirety via the following link:
https://onlinelibrary.wiley.com/doi/full/10.1111/wrr.12977
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/669452/Promore-Pharma-Announces-that-Scientific-Article-has-Been-Published-on-Clinical-Study-Results-with-Ropocamptide-for-Venous-Leg-Ulcers
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The 13th GLA Global Logistics Conference Successfully Concludes in Bangkok, Thailand5.12.2025 16:00:00 CET | Press release
More than 2,000 logistics leaders from 130+ countries convene in Thailand to advance peace, digital innovation and trustworthy cooperation in global supply chains. SHENZHEN, CN / ACCESS Newswire / December 5, 2025 / The 13th GLA Global Logistics Conference was successfully held in Bangkok, Thailand from November 7-10, 2025, providing a prestigious international platform for business cooperation in the global logistics sector. Co-organized by the Global Logistics Enterprises Federation (GLEF) and the GLA Global Logistics Alliance, the event centered around the theme "Peaceful Prosperity, Digital Innovation, Trustworthy Cooperation." The conference brought together over 2,000 logistics professionals and industry leaders from more than 130 countries, fostering a unique environment for collaboration and knowledge exchange. With its exceptional industry influence and capacity for cross-border resource integration, GLA continues to emerge as a pivotal force in driving global supply chain inn
OMP's AI-driven Unison Planning(TM) Platform Enhances Supply Chain Agility for McCormick & Co.3.12.2025 15:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / December 3, 2025 / OMP is helping McCormick & Co., the global leader in flavor, with an AI-driven and autonomous operational planning initiative. This partnership enables McCormick to manage both assembly-to-order (ATO) and make-to-stock (MTS) production within the Unison PlanningTM platform. The initiative tackles key challenges, including balancing ATO and MTS production on shared lines, improving inventory projections through quality-based stock releases, and managing capacity amid fluctuating demand. Addressing these challenges requires close collaboration across regions with North American and EMEA teams working in parallel, and seamless integration of SAP with the operational planning functionality within Unison Planning™. The first implementations will roll out in Canada and the United States before expanding to the EMEA and APAC regions. Through its partnership with OMP, McCormick is implementing autonomous, decision-centric planning powered
Oman's 10-Year Golden Residency Program Attracts Global Investors Seeking Stability and Long-Term Access3.12.2025 14:00:00 CET | Press release
Built for investors who value certainty, global access, and long-term confidence. MUSCAT, OM / ACCESS Newswire / December 3, 2025 / Three months after its introduction, Oman's 10-Year Golden Residency is emerging as one of the region's most compelling long-term residency pathways, attracting rising interest from investors, entrepreneurs, and internationally mobile families seeking stability, transparent regulation, and strategic access to high-growth markets. The programme-launched under Oman Vision 2040-offers a structured framework for investors wishing to establish deeper roots in a country positioning itself as a secure and globally connected economic hub.Prosperity and Liveability in Oman.jpg A contemporary Omani setting featuring growth, safety, and quality-of-life elements that define the country's reputation for prosperity and liveability. The Golden Residency grants eligible applicants long-term residency in return for a minimum investment of USD 520,000 across seven clearly d
Visit Qatar Presents Ludovico Einaudi Live in Doha3.12.2025 13:33:00 CET | Press release
DOHA, QA / ACCESS Newswire / December 3, 2025 / Visit Qatar presents one of the world's most celebrated composers and pianists, Ludovico Einaudi, to perform live in Doha on 9 January 2026 at the iconic Katara Amphitheatre. Doors open at 20:00 for an evening promising an extraordinary blend of emotion, artistry, and world-class music. Tickets are available at: https://doha.platinumlist.net/event-tickets/102626/ludovico-einaudi Known for his minimalist yet deeply evocative compositions, Ludovico Einaudi has captured global audiences with performances that seamlessly fuse classical tradition with contemporary sensibilities. His music, featured in internationally acclaimed films such as Nomadland and The Intouchables, has made him one of the most-streamed classical musicians worldwide. As Qatar continues to attract visitors from the region and around the world, the highly anticipated Ludovico Einaudi concert reflects Visit Qatar's commitment to hosting world-renowned talent and delivering
Nittetsu Mining Provides Final $1.5 Million Earn-in Payment for Camino's Los Chapitos Copper Project in Peru3.12.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / December 3, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the receipt of the sixth, and final, CAD$1.5 million payment from its exploration partner Nittetsu Mining CO., Ltd. ("Nittetsu"), marking the successful completion of Nittetsu's earn-in expenditure requirements under the earn-in agreement dated June 13, 2023 ("Earn-In Agreement") (see news release dated June 14, 2023). Following the conclusion of the current drilling program at the Los Chapitos Copper Project ("Los Chapitos" or the "Project") in Peru, the Project will be formally converted into a joint venture, with Camino retaining a 65% participating interest, operatorship of the Project, and 50% of the life-of-mine production off-take. Los Chapitos is the second joint venture project with Nittetsu, as Camino is currently advancing the Puquios copper mine development with Nittetsu in Chile. At Los Chapitos, exploration drilling has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom